Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results
March 06, 2025 16:10 ET – Enrollment completed in VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC); topline data expected in Q2 2025 – – VCN-01 development bolstered by FDA award of Fast Track designation for the treatment of PDAC and Rare Pediatric Disease designation for retinoblastoma – – Received […]
Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results Read More »